Last reviewed · How we verify
Rituximab (Arm B)
Rituximab works by targeting and depleting B cells, which are a type of immune system cell involved in the production of antibodies.
Rituximab works by targeting and depleting B cells, which are a type of immune system cell involved in the production of antibodies. Used for Non-Hodgkin lymphoma, Rheumatoid arthritis.
At a glance
| Generic name | Rituximab (Arm B) |
|---|---|
| Sponsor | Ostfold Hospital Trust |
| Drug class | Monoclonal antibody |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology, Immunology |
| Phase | Phase 3 |
Mechanism of action
Rituximab is a monoclonal antibody that binds to the CD20 antigen on the surface of B cells, leading to their destruction through a process called complement-dependent cytotoxicity. This results in a decrease in the number of B cells in the body, which can help to reduce inflammation and slow disease progression in conditions such as rheumatoid arthritis and non-Hodgkin lymphoma.
Approved indications
- Non-Hodgkin lymphoma
- Rheumatoid arthritis
Common side effects
- Infusion reactions
- Infections
- Neutropenia
- Thrombocytopenia
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia (PHASE1, PHASE2)
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (PHASE2, PHASE3)
- Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (PHASE2)
- A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma (PHASE2)
- Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (PHASE2, PHASE3)
- AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |